FMTVDM-Breast Cancers Diagnostic Doorway from Qualitative to Quantitative Measurement, Care and Treatment

Clinical efforts to diagnostically evaluate women-and men-with breast cancer have resulted in various degrees of success. The use of external radiographic sources to look for tissue abnormalities-mammography - has according to the Cochrane Collaboration not been able to demonstrate a reduction in mortality [1]; a position also held by the National Cancer Institute and The Canadian Trial [2].

Given the failure of mammograms to reliably find and exclude breast cancer, a variety of investigations looking at ultrasound, Magnetic Resonance Imaging (MRI) and Computer Tomography (CT), have failed to yield significantly better results.

In 2019, following efforts by DenseBreasts.org [3] and others, U.S. Federal Legislation was passed requiring all mammograms to include a statement specifying that women with dense breasts-which represents 50% of all women-need to be aware that mammograms may miss breast cancers in women whose breast tissue is considered dense.

During the last two-decades investigations into the ability to quantitatively measure changes in regional blood flow and metabolism-thus allowing differentiation of tissue-have demonstrated that FMTVDM* [4] can measure these tissue differences making it possible to distinguish between (A) inert material-calcium, breast implants, etc. – (b) normal breast tissue-including the fibroglandular tissue referred to as dense breast tissue, (C) inflammatory changes-including infections, (D) precancerous and ductal carcinoma in-situ, and (E) cancers [5-40].

As a result of these investigations, FMTVDM was patented [4] in 2017 and has been undergoing additional investigation in Nevada [41,42]. It is currently scheduled to be implemented in the curriculum of U.S. training programs [43] - thus opening the doorway between the worlds of qualitative and quantitative breast cancer diagnosis and treatment of patients.

*FMTVDM is issued to first author. No other COIs to report.

1. Gøtzsche PC, Jørgensen KJ (2013) Screening for breast cancer with mammography. Cochrane Database Syst Rev 6: CD001877. Link: https://bit.ly/2VichCJ
2. Miller AB, Wall C, Baines CJ, Sun P, ToT, et al. (2014) Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: a randomized screening trial. BMJ 348: g366. Link: https://bit.ly/3ebt4Qp
3. An Introduction to Dense Breast Tissue. Link: https://bit.ly/2Rv3FaH  
4. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons. Patent Number 9566037.
5. Fleming RM (2002) Breast enhanced scintigraphy test demonstrates improvement in breast inflammation in women consuming soy protein. American Society for Nutritional Sciences. J Nutr 132: 575S. Link: https://bit.ly/2Vj9clH
6. Fleming RM (2002) Mitochondrial Uptake of Sestamibi Distinguishes Between Normal, Inflammatory Breast Changes, Pre-cancers and Infiltrating Breast Cancer. Integr Cancer Ther 1: 229-237. Link: https://bit.ly/3ea35ZP
7. Fleming RM, Dooley WC (2002) Breast Enhanced Scintigraphy Testing (B.E.S.T.) Distinguishes Between Normal, Inflammatory Breast Changes and Breast Cancer. A Prospective Analysis and Comparison with Mammography. Integr Cancer Ther 1: 238-245. Link: https://bit.ly/3caR3xs
8. Fleming RM (2003) Are there differences in breast tissue as a result of hormone replacement therapy? Can BEST imaging distinguish these differences? Integr Cancer Ther 2: 229-234. Link: https://bit.ly/3eaWdet
9. Fleming RM (2003) Do women taking hormone replacement therapy (HRT) have a higher incidence of breast cancer than women who do not? Integr Cancer Ther 2: 235-237. Link: https://bit.ly/2xoPr4a
10. Fleming RM (2004) Breast Enhanced Scintigraphy Test demonstrates improvement in breast disease after daily consumption of soy protein. Amer. Institute Nutr 134: 1262S.
11. Fleming RM, Dooley WC, Chaudhuri TK (2017) Breast cancer genes, breast cancer and FMTVDM-BEST©℗ imaging. Integr Mol Med 4: 1-2. Link: https://bit.ly/2ySNlds
12. Fleming RM, Dooley WC, Chaudhuri TK (2017) The Development of FMTVDM-BEST IMAGING©℗: The Answer for Breast Cancer. Breast Enhanced Scintigraphy Test (BEST©℗): Quantifying the Detection of Breast Cancer and its Treatment. J Nucl Med Radiat Ther 8: 350. Link: https://bit.ly/2Rvvfoi
13. Fleming RM, Fleming MR, Dooley WC, McKusick A (2018) FMTVDM-BEST©℗ Breast Cancer Imaging eliminates the fear of having BRCA1 and BRCA2 Breast Cancer Genes. J Clin Mol Med 1: 1-2. Link: https://bit.ly/34qwBWH
14. Fleming RM, Fleming MR, Dooley WC, Sheikh A, McKusick A, et al. (2018) FMTVDM – FHRWW & B.E.S.T. The FIRST TRUE “Quantitative” Nuclear Imaging Protocols with Proprietary Equations following The Fleming Method (TFM) for Nuclear Scintillation Equipment Quantitative Standardization. Biomed J Sci Tech Res 4: 1-4. Link: https://bit.ly/2K98ORT
15. Fleming RM, Fleming MR, McKusick A, Chaudhuri T (2018) FMTVDM-TFM©℗: True Quantification requires Standardization of the tool being used to Measure, with a Known, Unchanging Standard to produce accurate, consistent and reproducible Quantified Measurements. J Nucl Card 26: 1780-1783. Link: https://bit.ly/2ySNKwu
16. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A (2018) FMTVDM; B.E.S.T.©℗ Imaging Theranostically Used to Guide Treatment Response in a woman With Recalcitrant Breast Cancer. Biomed J Sci  Tech Res 11. Link: https://bit.ly/34ursNp
17. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) Theranostic Information Provided by FMTVDM©℗; B.E.S.T. ©℗ Imaging. Adv Hema Onco Res 2: 1-3. Link: https://bit.ly/2XoT6tz
18. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A (2019) FMTVDM-BEST (B.E.S.T.) Breast Cancer Imaging Test (BBCIT): An Enhanced Quantitative Method for Performing Molecular Breast Imaging (MBI). Annals of Biomedical Imaging 11: 1001. Link: https://bit.ly/34tgiYX
19. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A (2019) FMTVDM/BEST Imaging For Women with Breast Implants and Dense Breasts. Int J Women’s Health Wellness 5: 092. Link: https://bit.ly/2JWBZr5
20. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A (2019) Unmasking Hidden Recurrent Cancers using FMTVDM/BEST. The Fleming Cancer Hypothesis. Int J Women’s Health Wellness 5: 094. Link: https://bit.ly/3a1t823
21. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A (2019) FMTVDM/BEST Imaging Equally Applicable for Male Breast Cancer. Int J Women’s Health Wellness 5: 93. Link: https://bit.ly/2Xti1MI
22. Fleming RM, Fleming MR, Chaudhuri TK, McKusick A, Dooley WC (2019) Proposed Breast Lump (FMTVDM/BEST) Pathway Nuclear Imaging Protocol. Adv Can Res Clinical Imag 1: 1-3. Link: https://bit.ly/3c93MR3
23. Fleming RM, Fleming MR, Chaudhuri TK, McKusick A, Dooley WC (2019) Statistical demonstration that FMTVDM is superior to mammography. Ann Clin Radiol 2: 1012. Link: https://bit.ly/34s8B5q
24. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) Simultaneous Quantitative Cardio Oncology Imaging Now Possible Using FMTVDM. Biomed J Sci  Tech Res 20: 15138-15143. Link: https://bit.ly/3c3TJN8
25. Fleming RM, Fleming MR, Chaudhuri TK, McKusick A (2019) Machine Learning through FMTVDM Proprietary QCA Equations. J Angiol Vasc Surg 4: 026. Link: https://bit.ly/2wvhjDm
26. Fleming RM, Fleming MR, Chaudhuri TK, McKusick A (2019) FMTVDM Quantitative Imaging Replaces Current Qualitative Imaging for Coronary Artery Disease and Cancer, Increasing Diagnostic Accuracy and Providing Patient- Specific, Patient-Directed Treatment. Cardio Open 4: 1-2. Link: https://bit.ly/34urV27
27. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) Part I: Proposed New Standards of Care for the Work up of Chest Pain and Breast Lumps. J Emer Med Prim Care 2: 1-3. Link: https://bit.ly/3b3jk8K
28. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) Part II: Proposed New Standards of Care for the Work up of Chest Pain and Breast Lumps. J Emer Med Prim Care 2: 1-3. Link: https://bit.ly/2RtK8XY
29. Fleming RM, Fleming MR, Dooley WC, Chaudhuri TK (2019) Breast Cancer: Knowing is More Important than Wondering. Acta Scientific Med Sci 3: 10. Link: https://bit.ly/3cbvqgs
30. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) How to Follow the Cancer Risk of Women with Breast Implants. LOJ Nur Heal Car 2: 194-197. Link: https://bit.ly/3cdswI7
31. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) Identifying Cancer in a Woman with a Breast Implant Following Prior Mastectomy for Breast Cancer. Acta Scientific Pharm Sci 3: 20-21. Link: https://bit.ly/2VifnGR
32. Fleming RM, Fleming MR, McKusick A, Chaudhuri TK (2018) Semi-quantification limitations: FMTVDM©℗ demonstrates quantified tumor response to treatment with both regional blood flow and metabolic changes. J Nucl Med 59: 1643-1644. Link: https://bit.ly/3c7YNAa
33. Fleming RM, Fleming MR, McKusick A, Chaudhuri TK (2018) FMTVDM©℗ Nuclear Imaging Artificial (AI) Intelligence but first we need to clarify the use of (1) Stress, (2) Rest, (3) Redistribution and (4) Quantification. Biomed J Sci  Tech Res 7: 1-4. Link: https://bit.ly/2RoWzVd
34. Fleming RM, Fleming MR, McKusick A, Chaudhuri TK (2018) Virtual quantification is not True quantification. FMTVDM-TFM©℗ Provides True quantification for SPECT and PET. Arch Med 10: 1-3. Link: https://bit.ly/2XsFFbS
35. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A (2019) Letter to the Editor: A response to Hruska’s case study on molecular breast imaging and the need for true tissue quantification. Breast Cancer Res 21: 15. Link: https://bit.ly/3cepfIf
36. Fleming RM, Fleming MR, Chaudhuri TK (2019) FMTVDM provides first patented Quantitative Method to accurately Measure both Heart Disease and Breast Cancer on the “Health-Spectrum”. J Cardiovasc Med Cardiol 6: 019-020. Link: https://bit.ly/3egrMDC
37. Fleming RM, Fleming MR (2019) The Importance of Thinking about and Quantifying Disease like Cancer and Heart Disease on a “Health-Spectrum” Continuum. J Compr Cancer Rep 3: 1-3. Link: https://bit.ly/2yK93QD
38. Fleming RM, Fleming MR, Chaudhuri TK, McKusick A, Dooley WC (2019) Nuclear Imaging: Physician Confusion Over True Quantification and Isotope Redistribution. J Clin Cases Rep 3: 32-42. Link: https://bit.ly/3c9yN7p
39. Fleming RM, Fleming MR, Chaudhuri TK (2019) The Need to Actually Measure What We’re Talking about before We Put it All Together. Int J Nuclear Med Radioactive Subs 2: 000114.
40. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) What is Cancer? Cancer Research in Oncology. 2:1-4. Link: https://bit.ly/2V1DF99 
41. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) How to Follow the Cancer Risk of Women with Breast Implants. LOJ Nur Heal Car 2: 194-197. Link: https://bit.ly/39YtNRO
42. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC (2019) Identifying Cancer in a Woman with a Breast Implant Following Prior Mastectomy for Breast Cancer. Acta Scientific Pharm Sci 3: 20-21. Link: https://bit.ly/2VifnGR
43. (2019) FMTVDM: The Fleming Method for Tissue and Vascular Differentiation and Metabolism Using Same State Single or Sequential Quantification Comparisons. Evidence Based Medicine. Link: https://bit.ly/3b2eUPw

© 2020 Fleming RM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.